NCT07778628Completed
WT1 in Colorectal Adenocarcinoma
Significance of Immunohistochemical Expression of Wilms' Tumor 1 (WT1) in Colorectal Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors. Detection of WT1 in colorectal carcinoma may provide better future results.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 18 Aug 2026
- Start date
- Jan 2022
- Primary completion date
- Dec 2025
- Lead sponsor
- Sohag University
- Diseases
- Kidney cancer, Colorectal cancer, Childhood cancers
- NCT number
- NCT07778628
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From Jan 2022 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients who received pre-operative neoadjuvant therapy.
Who the study is looking for
- patients with colorectal adenocarcinoma.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Sohag University Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.